LED LIGHT SOURCE FOR PHOTDYNAMIC THERAPY

用于光动力治疗的 LED 光源

• 批准号: 3492892
• 负责人: DANIEL R DOIRON
• 金额: $ 5万
• 依托单位: PDT SYSTEMS
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-09-18 至 1992-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3492892
• 关键词: clinical biomedical equipment; diagnosis design /evaluation; diagnosis quality /standard; diagnostic tests; laboratory rat; laser therapy; light emission; neoplasm /cancer diagnosis; neoplasm /cancer photoradiation therapy; photosensitizing agents; phototherapy

Photodynamic therapy, PDT, is presently undergoing extensive basic, preclinical and clinical testing for the diagnosis and treatment of cancer. Regulatory approval for the first PDT drug, Photofrin-II is expected in late 1991. Concurrent with this is the introduction of a number of second generation PDT drugs into clinical trials. all of these clinical trials are based on the use of laser light sources for the activation of the photosensitizing drug. A laser light source, though, is not required for those non-endoscopic applications using surface illumination. It is the aim of this phase-I project to develop and test a prototype light emitting diode (LED) source for PDT of external surface lesion using second generation photosensitizers. The LED offers a potential cost effective, efficient and effective light source for a number of PDT applications. Its extremely small size permits the use of multiple LED, or arrays, to provide a sufficient irradiance to activate the PDT therapeutic reaction in-vivo. The prototype system will include simultaneous delivered space irradiance measurement of the delivered light, along with thermal monitoring at the tissue/LED interface. A prototype system will be tested in a rat tumor system using the PDT drug, SnET2. In phase-II a clinical prototype system will be developed and tested in humans with the SnET2 or other new PDT drugs. If the system can be developed into a easy to use clinical system, its application in PDT would be significant, especially with the new photosensitizers that have absorption at longer wavelengths and exhibit minimal skin photosensitivity problems. The commercial potential of such a system would be great since it would lower cost and therefore make the PDT procedure a potential office type treatment.

光动力疗法（PDT）目前正在进行广泛的基础、 癌症诊断和治疗的临床前和临床测试。 首个 PDT 药物 Photofrin-II 预计将于 2020 年获得监管部门批准 1991 年底。与此同时推出的是一些第二个 一代PDT药物进入临床试验。 所有这些临床试验 基于使用激光光源来激活 光敏药物。 然而，不需要激光光源 那些使用表面照明的非内窥镜应用。 它是 该第一阶段项目的目标是开发和测试原型发光 使用第二个二极管 (LED) 源进行外表面病变的 PDT 一代光敏剂。 LED 提供了潜在的成本效益， 适用于多种 PDT 应用的高效光源。 它是 极小的尺寸允许使用多个 LED 或阵列，以提供 足够的辐照度来激活体内 PDT 治疗反应。 该原型系统将包括同时传输的空间辐照度 测量所传递的光，以及热监测 组织/LED 接口。 原型系统将在大鼠肿瘤中进行测试 系统使用 PDT 药物 SnET2。 临床原型系统处于二期阶段 将使用 SnET2 或其他新的 PDT 进行开发和人体测试 药物。 如果该系统能够开发成易于使用的临床系统， 它在 PDT 中的应用将具有重要意义，尤其是新的 光敏剂在较长波长下具有吸收并表现出 最小的皮肤光敏问题。 此类产品的商业潜力 一个系统会很棒，因为它可以降低成本，从而使 PDT 程序是一种潜在的办公室类型治疗。